Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Trius Therapeutics,'s
Operating Income
for the
three
months ended in Jun. 2013 was €-14.35 Mil. Trius Therapeutics,'s Interest Expense for the
three
months ended in Jun. 2013 was €0.00 Mil.
Trius Therapeutics, has no debt.
The higher the ratio, the stronger the company's financial strength is.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Trius Therapeutics,'s Interest Coverage or its related term are showing as below:
FRA:TEU'
s Interest Coverage Range Over the Past 10 Years
Min: 0 Med: 0 Max: No Debt
Current: No Debt
FRA:TEU's Interest Coverage is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 9.39
vs FRA:TEU: No Debt
Trius Therapeutics, Interest Coverage Historical Data
The historical data trend for Trius Therapeutics,'s Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Trius Therapeutics,'s Interest Coverage
For the Diagnostics & Research subindustry, Trius Therapeutics,'s Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trius Therapeutics,'s Interest Coverage Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Trius Therapeutics,'s Interest Coverage distribution charts can be found below:
* The bar in red indicates where Trius Therapeutics,'s Interest Coverage falls into.
Trius Therapeutics, Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Trius Therapeutics, Interest Coverage Related Terms
Thank you for viewing the detailed overview of Trius Therapeutics,'s Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Trius Therapeutics, (FRA:TEU) Business Description
Trius Therapeutics, Inc., was incorporated in California in June 2004. It is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company is developing tedizolid phosphate, a new, novel antibiotic, for the treatment of serious Gram-positive bacterial infections, including those caused by methicillin-resistant staphylococcus aureus, or MRSA. Tedizolid phosphate is being developed for acute bacterial skin and skin structure infections, or ABSSSI, and pneumonia, and potentially for other indications. ABSSSI is the current classification for complicated skin and skin structure infections. In addition, the company is discovering antibiotics for infections caused by Gram-negative bacteria using its structure based discovery platform. In December 2011, it reported top line data from its first Phase 3 clinical trial, the ESTABLISH 1 (TR701-112) study, of the oral dosage form of tedizolid phosphate for the treatment of ABSSSI. All primary and secondary endpoints for the ESTABLISH 1 study were achieved. In December 2012, the company completed enrollment in its second Phase 3 clinical trial, the ESTABLISH 2 (TR701-113) study, of the intravenous to oral transition therapy for the treatment of ABSSSI. Its current development efforts are focused on developing tedizolid phosphate (formerly known as torezolid phosphate), an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. Its strategy is to discover and develop a pipeline of antibiotics focused on the treatment of life-threatening infections, consisting of tedizolid phosphate and additional compounds discovered internally using its proprietary discovery platform. The Company employs the services of Albany Molecular Research Incorporated to produce tedizolid phosphate API and Patheon, Inc., or Patheon, to produce the solid oral and sterile IV tedizolid phosphate finished products. It currently employs internal resources and third-party consultants to manage its manufacturing contractors. Its competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. The Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products to the extent it choose to sell any products outside of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:TEU has been successfully added to your 